ECTRIMS: EMD Serono Highlights Risk-Benefit Profile of Cladribine Tablets for Relapsing MS

 

Data from a post-hoc analysis presented by Merck at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris show that investigational Cladribine Tablets significantly increases the proportion of patients with relapsing multiple sclerosis (MS) in high disease activity subgroups with no evidence of disease activity (NEDA) compared with placebo (43.7% vs. 8.7%). The company also shared late-breaking safety analyses including patients with up to eight-years follow-up from monotherapy oral (3.5 mg/kg) cohorts reinforcing safety conclusions of the earlier meta-analysis, as well as an analysis of T lymphocyte (T cells) subpopulations from the ORACLE-MS study demonstrating changes that occur in the adaptive immune system following Cladribine Tablets treatment.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC